Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Gemtuzumab Ozogamicin

It received a positive opinion for the treatment of acute myeloid leukaemia in patients aged 15 years and above
06 Mar 2018
Haematologic malignancies;  Anticancer agents & Biologic therapy

On 22 February 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product gemtuzumab ozogamicin (Mylotarg), intended for the treatment of acute myeloid leukaemia in patients aged 15 years and above, giving young patients a new treatment option. 

Mylotarg was designated as an orphan medicinal product on 18 October 2000. 

The applicant for this medicinal product is Pfizer Limited. 

Mylotarg will be available as a 5 mg powder for concentrate for solution for infusion. The active substance of Mylotarg is gemtuzumab ozogamicin, a humanised immunoglobulin G subtype 4 (IgG4) antibody (ATC code: L01XC05) directed at CD33 which is conjugated to calicheamicin, a toxin which induces breaks in double-stranded DNA, subsequently inducing cell cycle arrest and apoptotic cell death. 

The benefit with Mylotarg is improvement in event-free survival. 

The most common (> 30%) side effects of Mylotarg when used together with daunorubicin and cytarabine are haemorrhage and infection. 

The full indication is: “Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).” 

It is proposed that Mylotarg should be prescribed by physicians experienced in the use of anticancer medicinal products. 

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission. 

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion. 

Last update: 06 Mar 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.